The expected duration of training is two-years with an optional third-year for selected fellows, and incorporates a core comprehensive training curriculum in the foundations of clinical pharmacology, pharmacogenetics, and pharmacometrics with a focus on individualized pediatric therapeutics. The program will implement a rigorous, highly structured, and mentored clinical scholar program in pharmacology-related research that is broad, cross disciplinary and focused on clinical pharmacology and experimental therapeutics. In addition to participation in the core program curriculum, enrollees will select an academic focus area related to pediatric pharmacology and predictive translational medicine for mentored career training. Current focus areas include clinical and developmental pharmacology, population PK/PD modeling and simulation, pharmacometrics, pediatric clinical trial design, pharmacogenetics and pharmacogenomics, and Bayesian approaches to precision dosing.

Program Content

Fellowship training includes a diverse set of experiences in research, clinical service, program development, teaching/mentorship, and consultation as outlined in the core training elements overview, goals and objectives and sample curriculum.

Mentoring Philosophy

Our training program is highly individualized. Based on dialogue with Program faculty, our training program is tailored to individual interests' and career development needs with respect to the balance of research and clinical care as well as specific content areas of focus. Fellows are expected to take initiative for their individual projects and training program in the context of close and collegial mentorship from faculty and are assigned a primary mentor in their focus area. 

Program leaders and mentors are established senior investigators with National Institutes of Health-funded programs in pediatric clinical research. In close collaboration with his or her primary mentor, the program enrollee will focus in a specific area of novel drug development or individualized therapeutics including development of pharmacokinetic/pharmacogenetic assays and analysis, and/or development of biomarker assays for pharmacodynamic measurement and endpoints. It is anticipated that these activities will include a mentored development of a pediatric Phase I/II clinical study as well as training in the development and writing of extramural funding applications (e.g., NIH K-, and R-series grants).